cafepharma5 successful phase III oncology trials in Q1—FDA gives nod to BrainStorm for ALS trial after Phase III flop—AbbVie’s Humira loses only 4% of market share to biosimilars--http://bit.ly/w28kSd #clinicaltrials #oncology #fda #als #abbvie #humira #biosimilars #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
